


Supplemental Figure 1. Greater than efficiency curves evaluating the effect of estradiol on adverse placental outcomes. The occurrence of various adverse outcomes was calculated above each estradiol threshold in increments of 500 pg/ml.

Supplemental Figure 2. Greater than efficiency curves evaluating the effect of estradiol on adverse placental outcomes in ICSI patients without male factor (-MF) and with male factor (+MF). The occurrence of adverse outcomes was calculated above each estradiol threshold in increments of 500 pg/ml.

Supplemental Table 1. Associations of estradiol and ICSI with individual and composite adverse events.

Supplemental Table 1. Associations of estradiol and ICSI with individual and composite adverse events.

<b>Variable</b>	<b>Peak Estradiol (per 1000 pg/ml)</b>		<b>ICSI</b>	
	<b>Odds Ratio (95% CI)</b>	<b>P value</b>	<b>Odds Ratio (95% CI)</b>	<b>P value</b>
Preterm delivery	1.00 (0.99-1.01)	0.67	2.53 (0.30-20.80)	0.38
IUGR	1.08 (0.64-1.81)	0.76	1.06 (0.21-5.34)	0.94
SGA	1.58 (1.23-2.03)	<0.001	5.90 (1.38-25.1)	0.01
GHTN	1.52 (1.05-2.21)	0.02	0.78 (0.23-2.61)	0.69
Pre-eclampsia	2.18 (1.04-4.54)	0.03	3.92 (0.90-17.0)	0.06
Any growth disorder	1.66 (1.28-2.15)	0.01	6.85 (1.57-29.8)	0.01
Any hypertensive disorder	1.46 (1.15-1.86)	0.002	2.02 (0.80-5.09)	0.13
Any adverse placental outcome	1.36 (1.13-1.65)	0.001	4.21 (1.73-10.2)	0.002



Supplemental Figure 2

